These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 23875536)

  • 1. SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.
    Jacquemier J; Spyratos F; Esterni B; Mozziconacci MJ; Antoine M; Arnould L; Lizard S; Bertheau P; Lehmann-Che J; Fournier CB; Krieger S; Bibeau F; Lamy PJ; Chenard MP; Legrain M; Guinebretière JM; Loussouarn D; Macgrogan G; Hostein I; Mathieu MC; Lacroix L; Valent A; Robin YM; Revillion F; Triki ML; Seaume A; Salomon AV; de Cremoux P; Portefaix G; Xerri L; Vacher S; Bièche I; Penault-Llorca F
    BMC Cancer; 2013 Jul; 13():351. PubMed ID: 23875536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH).
    Arnould L; Roger P; Macgrogan G; Chenard MP; Balaton A; Beauclair S; Penault-Llorca F
    Mod Pathol; 2012 May; 25(5):675-82. PubMed ID: 22222637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
    Francis GD; Jones MA; Beadle GF; Stein SR
    Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison between analysis of HER2 gene and chromosome 17 in breast cancer by dual-probe chromogenic in situ hybridization and fluorescence in situ hybridization].
    Bai YF; Ren GP; Wang B; Teng LS; Liu X
    Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):161-5. PubMed ID: 20450761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens.
    Shousha S; Peston D; Amo-Takyi B; Morgan M; Jasani B
    Histopathology; 2009 Jan; 54(2):248-53. PubMed ID: 19207950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
    Zhao J; Wu R; Au A; Marquez A; Yu Y; Shi Z
    Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Her2 amplification: correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization.
    Wixom CR; Albers EA; Weidner N
    Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):248-51. PubMed ID: 15551739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer.
    Arnould L; Denoux Y; MacGrogan G; Penault-Llorca F; Fiche M; Treilleux I; Mathieu MC; Vincent-Salomon A; Vilain MO; Couturier J
    Br J Cancer; 2003 May; 88(10):1587-91. PubMed ID: 12771927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer.
    Koh YW; Lee HJ; Lee JW; Kang J; Gong G
    Mod Pathol; 2011 Jun; 24(6):794-800. PubMed ID: 21317877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
    Kiyose S; Igarashi H; Nagura K; Kamo T; Kawane K; Mori H; Ozawa T; Maeda M; Konno K; Hoshino H; Konno H; Ogura H; Shinmura K; Hattori N; Sugimura H
    Pathol Int; 2012 Nov; 62(11):728-34. PubMed ID: 23121603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of chromogenic in situ hybridization (CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH.
    Li-Ning-T E; Ronchetti R; Torres-Cabala C; Merino MJ
    Int J Surg Pathol; 2005 Oct; 13(4):343-51. PubMed ID: 16273190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH).
    Kato N; Itoh H; Serizawa A; Hatanaka Y; Umemura S; Osamura RY
    Pathol Int; 2010 Jul; 60(7):510-5. PubMed ID: 20594272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance between HER-2 status determined by qPCR in Fine Needle Aspiration Cytology (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients.
    Rodriguez C; Suciu V; Poterie A; Lacroix L; Miran I; Boichard A; Delaloge S; Deneuve J; Azoulay S; Mathieu MC; Valent A; Michiels S; Arnedos M; Vielh P
    Mol Oncol; 2016 Nov; 10(9):1430-1436. PubMed ID: 27555543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of HER2 gene amplification in breast cancer using dual-color silver enhanced in situ hybridization (dc- SISH) and comparison with fluorescence ISH (FISH).
    Unal B; Karaveli FS; Pestereli HE; Erdogan G
    Asian Pac J Cancer Prev; 2013; 14(10):6131-4. PubMed ID: 24289638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists.
    Dietel M; Ellis IO; Höfler H; Kreipe H; Moch H; Dankof A; Kölble K; Kristiansen G
    Virchows Arch; 2007 Jul; 451(1):19-25. PubMed ID: 17562074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.
    van de Vijver M; Bilous M; Hanna W; Hofmann M; Kristel P; Penault-Llorca F; Rüschoff J
    Breast Cancer Res; 2007; 9(5):R68. PubMed ID: 17922920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer].
    Zhang GH; Shi DR; Liang XM; Hou JH; Kang SY; Zhu WD; Li XB; Shao Y; Chen LR; Zhou Y
    Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):580-3. PubMed ID: 17134562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility.
    Papouchado BG; Myles J; Lloyd RV; Stoler M; Oliveira AM; Downs-Kelly E; Morey A; Bilous M; Nagle R; Prescott N; Wang L; Dragovich L; McElhinny A; Garcia CF; Ranger-Moore J; Free H; Powell W; Loftus M; Pettay J; Gaire F; Roberts C; Dietel M; Roche P; Grogan T; Tubbs R
    Am J Surg Pathol; 2010 Jun; 34(6):767-76. PubMed ID: 20421783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.
    Riethdorf S; Hoegel B; John B; Ott G; Fritz P; Thon S; Loening T; Pantel K
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):261-9. PubMed ID: 20396915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
    Akhdar A; Bronsard M; Lemieux R; Geha S
    Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.